Pfizer's JAK1 challenger to Dupixent shines in another PhIII, but safety issues still cast a shadow
Pfizer is racking up ammunition for its full-on assault against Regeneron and Sanofi’s Dupixent franchise, with the latest topline win for an oral atopic dermatitis drug that it’s steering to the FDA later this year. But the new data cut is doing little to ease safety concerns.
JADE COMPARE is the third Phase III trial in the abrocitinib eczema program. Unlike JADE MONO-1 and JADE MONO-2, which enrolled patients who either don’t respond well or can’t tolerate topical treatment, this new trial zeroed in on those also taking topical therapies on background.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.